Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy (Micro & Nano Technologies). Dieser Artikel ist nicht verfügbar.Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy (Micro & Nano Technologies)

Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy reviews the principles and applications of nanocarriers for targeted drug delivery. Drug targeting involves active and passive strategies that exploit both the use of ligands for interactions and the physical and chemical properties of nanocarriers and micro-environments at target sites. Multidrug resistance and adverse side effects associated with anticancer drugs have attracted greater scientific attention and led formulation scientists to specifically target these drugs to target sites. Nanocarriers like liposomes, niosomes, gold nanorods, carbon nanotubes, and micelles are discussed for the delivery of drugs to specific disease sites.

This is an important reference source for researchers in the biomedical and biomaterials fields who want to gain an understanding on how nanotechnology is used for earlier diagnoses and more effective cancer treatment.

Prof. Muhammad Raza Shah is a professor and Director of the International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Pakistan. He holds four US patents. Dr. Shah has received numerous awards, including the Khwarizmi International Award from the Ministry of Science, Research and Technology, Iran (2023). He has also been honored with the Civil Award Tamgha-i-Imtiaz (2015), Dr. Raziuddin Prize (2015), Prof. Atta-ur-Rahman Gold Medal by the Pakistan Academy of Sciences, Avicenna Science & Innovation Award (2015) by Brain Trust UK, and the Abdus Salam Award in Chemistry (2006). He was named TWAS Young Affiliate in 2010 by The World Academy of Sciences. Prof. Shah is a Fellow of the International Union of Pure and Applied Chemistry, the Chemical Society of Pakistan, the Islamic World Academy of Sciences, and the Royal College of Physicians (Edinburgh). Dr. Shah has conducted 29 Phase-I (BE and PK) studies, 04 Phase-II Randomized Clinical Trial as PI and lead the Phase-I RCT of Sinopharm COVID-19 vaccine and Phase-III RCT of COVID-19 booster vaccine as country PI.

Muhammad Imran is a graduate student and based at the International Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry University of Karachi, Pakistan.

Shafi Ullah is a graduate student and based at the International Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry University of Karachi, Pakistan.